Immune Microenvironment in Osteosarcoma: Components, Therapeutic Strategies and Clinical Applications
Overview
Affiliations
Osteosarcoma is a primary malignant tumor that tends to threaten children and adolescents, and the 5-year event-free survival rate has not improved significantly in the past three decades, bringing grief and economic burden to patients and society. To date, the genetic background and oncogenesis mechanisms of osteosarcoma remain unclear, impeding further research. The tumor immune microenvironment has become a recent research hot spot, providing novel but valuable insight into tumor heterogeneity and multifaceted mechanisms of tumor progression and metastasis. However, the immune microenvironment in osteosarcoma has been vigorously discussed, and the landscape of immune and non-immune component infiltration has been intensively investigated. Here, we summarize the current knowledge of the classification, features, and functions of the main infiltrating cells, complement system, and exosomes in the osteosarcoma immune microenvironment. In each section, we also highlight the complex crosstalk network among them and the corresponding potential therapeutic strategies and clinical applications to deepen our understanding of osteosarcoma and provide a reference for imminent effective therapies with reduced adverse effects.
Hu Y, Yang R, Ni S, Song Z Front Immunol. 2025; 15:1485053.
PMID: 39995821 PMC: 11847827. DOI: 10.3389/fimmu.2024.1485053.
Manipulating the cGAS-STING Axis: advancing innovative strategies for osteosarcoma therapeutics.
Li B, Zhang C, Xu X, Shen Q, Luo S, Hu J Front Immunol. 2025; 16:1539396.
PMID: 39991153 PMC: 11842356. DOI: 10.3389/fimmu.2025.1539396.
Zhao X, Shan G, Xing D, Gao H, Xiong Z, Hui W World J Surg Oncol. 2025; 23(1):63.
PMID: 39988669 PMC: 11849225. DOI: 10.1186/s12957-025-03715-3.
Zhang S, Xing Z, Ke J J Bone Oncol. 2025; 50():100655.
PMID: 39850453 PMC: 11755076. DOI: 10.1016/j.jbo.2024.100655.
Liao S, Gao X, Zhou K, Kang Y, Ji L, Zhong X Heliyon. 2025; 11(1):e41358.
PMID: 39844989 PMC: 11750479. DOI: 10.1016/j.heliyon.2024.e41358.